MRIguidance’s Post

New featured CE! 🔗 https://bit.ly/4e8RVmL The blood-brain barrier (BBB) remains a significant blockade for effective drug delivery in treating diffuse intrinsic pontine glioma (DIPG). Low-frequency focused ultrasound (FUS) therapy in conjunction with intravenous microbubbles can transiently disrupt the BBB in a localized manner to facilitate drug delivery. This review examines recent preclinical studies evaluating the safety and feasibility of FUS-mediated BBB opening in the brainstem. #CME #MedEd #RadEd

We enjoyed a dynamic panel discussion on ‘Improving Target Specificity and Delivery Technologies for Oligonucleotide Therapeutics.’ The session delved into: - Updates in LNP technologies for targeted oligonucleotide delivery -Extrahepatic delivery: how far have we come and what is still needed to meet industry acceleration - Looking to the future: what lies ahead for technologies to improve target specificity of ASO delivery? A big thank you to our panelists: Nagy Habib, Professor of Surgery, Imperial College London, and Co-Founder of MiNA, Apterna, and Dawn Therapeutics Alessandro Bonetti, Principal Scientist, R&D Biopharmaceuticals, AstraZeneca Stefan Rathjen, PhD, Senior Scientist, Drug Delivery, Silence Therapeutics plc Your insights were invaluable! Check out the agenda to see what else we have instore today➡https://ow.ly/RQyj50Tk1jI Exhibitors: Aptamer Group | Asymchem Group | ChemGenes #OligoTherapeutics #OligoResearch #NucleicAcidTherapeutics #GeneTherapy #RNAi #ASOs #Biotechnology #PrecisionMedicine #PharmaInnovation #TherapeuticDevelopment #Biopharma #GeneticMedicine #MolecularBiology #OligoTx

🌐 NanoVation Therapeutics at ETPN 2024: The future of nanomedicines and their translation into the clinic  🌐   Our CEO, Dominik Witzigmann, PhD, will be a featured speaker at the European Technology Platform on Nanomedicine (ETPN Association) Meeting 2024 in Milan, taking place from June 10-12.   🎤 Presentation Spotlight: In his talk, "Breaking the delivery barrier: Next-generation lipid nanoparticle technologies for nucleic acid delivery to extrahepatic tissues," Dom will detail our latest advancements. NanoVation LNP innovations are enabling the targeted delivery of nucleic acids to tissues beyond the liver.    🤝 Why We Joined ETPN? Discover why joining ETPN aligns perfectly with our vision and how it enhances our work in genetic medicines. Watch our CEO, Dom, share insights on our collaborative efforts to drive healthcare innovation in this exclusive video: https://lnkd.in/ewHPquzy   #ETPN2024 #Nanomedicine #Innovation #Healthcare #NanoVationTherapeutics #genetherapy #RNA #Nucleicacid

🔬 T1 Contrast Imaging with ESIONs (feat. SimPET) 🔬 Extremely small-sized iron oxide nanoparticles (ESIONs) hold promise in overcoming the limitations of traditional iron oxide nanoparticles (IONPs) as T1 contrast agents. 📋 Study Insights: ESIONs achieved a consistent size (9.35 nm) and favorable r1 relaxivity (3.43 mM−1s−1) with a reduced r2/r1 ratio (5.36), key for T1 contrast enhancement. Extended circulation times and hepatobiliary clearance pathways were observed, with minimal renal excretion. Preclinical assessments confirmed tolerability at doses up to 25 mg/kg. With tools like SimPET, the study utilized advanced imaging to monitor blood clearance and organ distribution of ESIONs, demonstrating their potential for clinical applications such as tumor imaging, live-cell tracking, and hyperthermia therapy. This work highlights the clinical promise of ESIONs, paving the way for safer, more effective contrast imaging solutions. #BrightonixImaging #SimPET #IronOxideNanoparticles #T1ContrastAgents #PreclinicalResearch #Nanomedicine #MedicalImaging #MR 👇 Find out more below! Optimization of micelle-encapsulated extremely small sized iron oxide nanoparticles as a T1 contrast imaging agent: biodistribution and safety profile

Are you working on the development of novel #Molecular #RadioTherapy agents? This poster could be of interest for you! It describes the differents approaches at Oncodesign Services to support the development of radiopharmaceuticals: ▶️Lead optimization ▶️Bioconjugaison chemistry ▶️3D models ▶️In vivo models ▶️ PET-Imaging and SPECT-Imaging monitoring... Discover more information👇 https://lnkd.in/eAAMBmGY #Radiopharmaceutical #Theranostics #Innovation #Imaging #Radiotherapy #DrugDevelopment

Important new milestone for #Novadip's NVDX3 securing IND approval from the FDA to initiate a phase 2b/3 study in cervical spine fusion. Built upon robust preclinical and clinical datasets, NVDX3 has potential to replace existing allogenic bone grafting materials – providing patients with complex comorbidities better bone fusion success. "The trial will accelerate our capability to bring NVDX3 to patients with complex needs, providing them with a better chance of healing compared to standard-of-care treatments. These strategic steps enable us to take NVDX3 to the next level,” said Denis Dufrane, MD, PhD, CEO of NOVADIP Biosciences S.A. 👉 Read the full release: https://lnkd.in/dUHwjR2F

Through dedicated innovation and development, alpha radiopharmaceuticals and new solid-state detector SPECT systems empower nuclear medicine to remain at the forefront of oncology treatment. Very interesting and educative video below - thanks to the efforts of the scientists and educators in this field! 👏 #nuclearmedicine #molecularimaging #alphatherapy #Spectct

Ophthopedia Update:Impact of a Recall of Intravitreal Bevacizumab: A HALO Registry Review: Intravitreal use of bevacizumab (IVB) was first reported nearly two decades ago for neovascular age-related macular degeneration (nAMD).1 Subsequently, IVB was shown to be non-inferior to ranibizumab for the treatment of nAMD in a large randomized clinical trial.2 Since then, the use of IVB has been widespread across retinal pathologies. #Ophthalmology #Retina #Ophthotwitter

Histology and Cytology Market to Reach USD 22.2 Billion by 2032, Driven by the Widespread Adoption of Histological and Cytological Analysis in Clinical Diagnostics https://lnkd.in/gj8NaJTa #marketanalysis #marketresearch #marketresearchreports #businessintelligence

WPI EVOM™ instruments for TEER measurement have been cited in 30 publications in the last month for applications including: • Epithelial barrier studies • Blood brain barrier studies • Lung epithelial and gastro-intestinal studies • Bioengineering • Drug therapy analyses and drug development • Toxicity studies • Organoids • Ophthalmic studies Review all the EVOM™ cited publications. https://lnkd.in/gFHuNbYM